Tech Company Financing Transactions
Adicet Bio Funding Round
Adicet Bio secured a $51 million Series A venture capital round on 1/28/2016. Investors included OrbiMed, Novartis Venture Fund and Pontifax Fund.
Transaction Overview
Company Name
Announced On
1/28/2016
Transaction Type
Venture Equity
Amount
$51,000,000
Round
Series A
Investors
Proceeds Purpose
These significant financial resources will allow Adicet to progress its universal immune cell therapy (uICT) platform technology and related products and advance AIT's programs and product pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 Constitution Dr.
Menlo Park, CA 94025
USA
Menlo Park, CA 94025
USA
Phone
Undisclosed
Website
Email Address
Overview
Adicet Bio, Inc. is a biotechnology company engaged in the design and development of cutting-edge immunotherapies for cancer and other disease indications, with a focus on novel universal immune cell therapies (uICT).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Donald Santel
Chief Executive Officer
Anil Singhal
Chief Financial Officer
Brian Hogan
Chief Medical Officer
Francesco Galimi
Chief Operating Officer
Stewart Abbot
Founder
Aya Jakobovits
VP - Human Resources
Carrie Krehlik
Browse more venture capital transactions:
Prev: 1/28/2016: Mercatus venture capital transaction
Next: 1/28/2016: Photobucket venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs